天津红日药业股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 天津红日药业股份有限公司（以下简称"公司"）于 2025 年 10 月 27 日召开 了第九届董事会第三次会议及第九届监事会第三次会议，审议通过了《关于公司 2025 年前三季度计提资产减值准备的议案》，议案已经公司董事会审计委员会审 议通过，该事项无需提交公司股东大会审议批准。现将具体情况公告如下： 一、本次计提资产减值准备情况概述 证券代码：300026 证券简称：红日药业 公告编号：2025-055 天津红日药业股份有限公司 关于公司 2025 年前三季度计提资产减值准备的公告 （一）本次计提资产减值准备的原因 为真实反映公司的财务状况和资产价值，依据《企业会计准则》及公司会计 政策的相关规定，公司及子公司于 2025 年 9 月 30 日对应收款项、存货等各类资 产进行了检查，并对存在可能发生减值迹象的金融资产在整个存续期内的预期信 用损失、各类存货的可变现净值进行了分析和评估，在此基础上对发生资产减值 损失的资产计提减值准备。经测算，2025 年 1-9 月公司计提减值损失合计 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 特别提示：天津红日药业股份有限公司（以下简称"公司"）于2025年10 月27日召开了第九届董事会第三次会议及第九届监事会第三次会议，审议通过了 《关于公司<2025年第三季度季度报告>的议案》。公司2025年第三季度报告于 2025年10月29日在深圳证券交易所网站和符合中国证监会规定的创业板信息披 露网站上披露，请投资者注意查阅。 证券代码：300026 证券简称：红日药业 公告编号：2025-051 天津红日药业股份有限公司 2025 年第三季度报告披露提示性公告 天津红日药业股份有限公司 特此公告。 天津红日药业股份有限公司 董 事 会 二○二五年十月二十八日 1 ...

天津红日药业股份有限公司 关于召开 2025 年第三次临时股东大会的通知 天津红日药业股份有限公司 证券代码：300026 证券简称：红日药业 公告编号：2025-057 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、召开会议的基本情况 1、股东大会届次：2025 年第三次临时股东大会 2、股东大会的召集人：董事会 3、会议召开的合法、合规性：本次会议的召集、召开符合《中华人民共和 国公司法》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自 律监管指引第 2 号—创业板上市公司规范运作》等法律、行政法规、部门规章、 规范性文件及《公司章程》的有关规定。 4、会议时间： （1）现场会议时间：2025 年 11 月 17 日 14:30 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2025 年 11 月 17 日 9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易 所互联网投票系统投票的具体时间为 2025 年 11 月 17 日 9:15 至 15:00 的任意时 间。 （1）现场投票： ...

天津红日药业股份有限公司 证券代码：300026 证券简称：红日药业 公告编号：2025-054 天津红日药业股份有限公司 第九届监事会第三次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 天津红日药业股份有限公司（以下简称"公司"）第九届监事会第三次会议 于 2025 年 10 月 27 日在天津市武清开发区创业总部基地 B01 号楼公司会议室以 现场加通讯表决方式召开,会议通知于 2025 年 10 月 16 日以邮件、电话的方式发 出。会议应参加监事 3 人，实际参加会议的监事 3 人（其中以通讯表决方式出席 会议的监事为 2 人）。本次会议以通讯表决的监事分别为：监事会主席叶尚书女 士、监事李俊先生。公司部分高级管理人员列席了会议。本次会议召开符合《公 司法》等相关法律法规和《公司章程》《公司监事会议事规则》的有关规定。 会议由公司监事会主席叶尚书女士主持，参会监事投票表决通过如下议案： 一、审议通过《关于公司<2025 年第三季度季度报告>的议案》； 监事会认为：公司董事会编制及审议公司《2025 年第三季度报告》的程序 符合法律、行政 ...

Core Insights - Hongri Pharmaceutical reported a revenue of 1.354 billion yuan for Q3 2025, representing a year-on-year decline of 6.32% [1] - The net profit attributable to shareholders was 2.1329 million yuan, down 89.40% year-on-year [1] - Basic earnings per share stood at 0.001 yuan [1] Financial Performance - For the first three quarters, the company achieved a revenue of 4.149 billion yuan, a decrease of 6.59% compared to the previous year [1] - The net profit attributable to shareholders for the same period was 80.7629 million yuan, reflecting a year-on-year decline of 52.03% [1] - Basic earnings per share for the first three quarters were 0.03 yuan [1]

Financial Performance - Q3 2025 revenue was CNY 1,353,594,654.88, a decrease of 6.32% year-over-year[5] - Net profit attributable to shareholders was CNY 2,132,915.33, down 89.40% compared to the same period last year[5] - Basic earnings per share decreased by 85.71% to CNY 0.001[5] - Total operating revenue for the current period is approximately ¥4.15 billion, a decrease of 6.6% compared to ¥4.44 billion in the previous period[20] - Net profit for the current period is approximately ¥91.93 million, a decline of 52.2% from ¥192.40 million in the previous period[21] - Earnings per share (EPS) for the current period is ¥0.03, down from ¥0.06 in the previous period[22] Assets and Liabilities - Total assets at the end of the reporting period were CNY 10,758,345,758.27, a decline of 3.64% from the previous year[5] - The company reported a total asset of ¥10,758,345,758.27 as of September 30, 2025, down from ¥11,165,116,699.53 at the beginning of the period, indicating a decrease of approximately 3.65%[16] - Total liabilities decreased from ¥2,366,561,176.36 to ¥1,962,784,651.56, indicating a reduction of about 17%[18] - Total equity attributable to shareholders of the parent company is approximately ¥8.64 billion, slightly down from ¥8.64 billion in the previous period[19] Cash Flow - Cash flow from operating activities for the year-to-date was CNY 536,836,636.49, an increase of 6.28%[5] - Cash flow from operating activities generated a net amount of approximately ¥536.84 million, an increase of 6.3% from ¥505.13 million in the previous period[22] - The ending cash and cash equivalents balance was $1.39 billion, up from $1.04 billion in the prior period[23] - The company reported a net increase in cash and cash equivalents of $113.02 million, contrasting with a decrease of $505.06 million in the previous period[23] Investments and Expenses - Investment income for the period was CNY -287.46 million, a decrease of 160.99% year-over-year[10] - Financial expenses decreased by 64.26% to CNY 10.05 million compared to the same period last year[10] - The company reported a decrease in research and development expenses to approximately ¥132.73 million, down from ¥154.10 million in the previous period[20] - The company’s long-term investments decreased from ¥12,964,808.38 to ¥10,160,633.03, a decline of approximately 21.5%[16] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 96,308[12] - The total number of restricted shares increased to 265,626,359 from 240,731,655, with an addition of 24,894,704 shares during the period[14] - The company has not disclosed any related party relationships among the top shareholders[13] Tax and Fees - The company needs to pay a total of ¥33,838,200 for tax and late fees, which includes ¥25,166,000 in taxes and ¥8,672,200 in late fees[15] Other Financial Metrics - Other comprehensive income after tax for the current period is approximately -¥308.94 thousand, compared to -¥1.51 million in the previous period[22] - The company experienced a net foreign exchange loss of approximately -¥45.77 million, compared to -¥50.47 million in the previous period[21] - Net cash flow from investment activities was -$93.36 million, a decrease from -$160.19 million in the previous period[23] - Cash inflow from financing activities totaled $51.26 million, compared to $36.08 million in the prior period[23] - Total cash outflow from financing activities was $381.02 million, down from $886.19 million year-over-year[23] - The net cash flow from financing activities was -$329.76 million, an improvement from -$850.11 million in the previous period[23] Audit Status - The company has not audited its third-quarter financial report[24]

Market Overview - The medical consumables supply chain SPD sector increased by 0.41% compared to the previous trading day, with Jianfa Zhixin leading the gains [1] - The Shanghai Composite Index closed at 3863.89, up 0.63%, while the Shenzhen Component Index closed at 12813.21, up 0.98% [1] Stock Performance - Jianfa Zhixin (301584) closed at 29.30, up 4.46% with a trading volume of 186,400 shares and a transaction value of 534 million [1] - Dajia Weikang (301126) closed at 11.75, up 3.07% with a trading volume of 53,500 shares and a transaction value of 62.22 million [1] - Jianmo Information (605186) closed at 19.55, up 2.68% with a trading volume of 17,200 shares and a transaction value of 33.43 million [1] - Other notable performers include Hefei China (603122) up 1.91%, Langma Information (300288) up 1.48%, and Seli Medical (603716) up 1.48% [1] Capital Flow - The SPD sector experienced a net outflow of 43.97 million from institutional investors, while retail investors saw a net inflow of 16.33 million [2] - The sector's overall capital flow indicates a mixed sentiment, with institutional investors pulling back while retail investors are more active [2] Individual Stock Capital Flow - Seli Medical (603716) had a net inflow of 12.83 million from institutional investors, but a net outflow of 12.61 million from speculative funds [3] - Dajia Weikang (301126) saw a net inflow of 5.24 million from speculative funds, but a net outflow of 5.91 million from retail investors [3] - Huadong Pharmaceutical (000963) had a net inflow of 2.37 million from speculative funds, while retail investors experienced a net outflow of 4.64 million [3]

Core Viewpoint - Hongri Pharmaceutical experienced a slight increase in stock price and trading volume, with notable financing activities indicating a mixed sentiment among investors [1][2]. Financing Activities - On October 16, Hongri Pharmaceutical recorded a financing buy-in amount of 21.19 million yuan, with a net financing buy of 3.67 million yuan after repayments [1]. - The total financing and securities balance reached 631 million yuan, accounting for 5.54% of the circulating market value, which is below the 10% percentile level over the past year, indicating a low financing level [1]. - The company had a securities lending balance of 1.14 million yuan, with a lending volume of 30,140 shares, which is above the 60% percentile level over the past year, suggesting a higher level of short selling [1]. Financial Performance - For the first half of 2025, Hongri Pharmaceutical reported a revenue of 2.795 billion yuan, a year-on-year decrease of 6.72%, and a net profit attributable to shareholders of 78.63 million yuan, down 46.95% year-on-year [2]. - Cumulatively, the company has distributed 1.116 billion yuan in dividends since its A-share listing, with 270 million yuan distributed over the past three years [3]. Shareholder Structure - As of June 30, 2025, the number of shareholders decreased by 2.01% to 100,800, while the average circulating shares per person increased by 1.98% to 27,160 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited increased its holdings by 5.77 million shares to 26.07 million shares, while Southern CSI 1000 ETF increased its holdings by 3.71 million shares to 19.46 million shares [3].

Core Points - Hongri Pharmaceutical Co., Ltd. announced a self-inspection regarding tax matters, resulting in a tax payment of 25.166 million yuan and late fees of 8.6722 million yuan, totaling 33.8382 million yuan [2] - The total amount of tax and late fees paid represents approximately 43% of the company's net profit for the first half of 2025, which was 78.63 million yuan [2] - The company stated that the tax payment and late fees will be included in the 2025 current profit and loss, with the final impact on net profit to be determined by audited financial statements [2] Company Actions - The proactive self-inspection and tax payment reflect the company's commitment to compliant operations, despite the short-term pressure on performance [3] - The company aims to avoid potential risks associated with tax issues by addressing the matter promptly [3]

Core Viewpoint - The Fujian Provincial Medical Security Bureau has announced the credit rating of two pharmaceutical companies, Beijing Kangrengtang Pharmaceutical Co., Ltd. and Guizhou Sanli Pharmaceutical Co., Ltd., both rated as "general" due to their involvement in commercial bribery cases [1][4]. Company Ratings - Beijing Kangrengtang Pharmaceutical Co., Ltd. was found to have engaged in bribery amounting to 46,000 yuan from 2013 to 2015 to medical institution personnel [2][4]. - Guizhou Sanli Pharmaceutical Co., Ltd. was involved in a bribery case where approximately 120,000 yuan was given to medical institution doctors to promote the prescription of its product, a children's throat spray [2][4]. Rating Criteria - The credit rating is based on the criteria set forth in the "Medical Price and Procurement Credit Rating Discretionary Standards" (2020 version), which states that companies involved in bribery exceeding 10,000 yuan but less than 150,000 yuan are rated as "general" [2][4].